A detailed history of Rhumbline Advisers transactions in Amgen Inc stock. As of the latest transaction made, Rhumbline Advisers holds 1,017,278 shares of AMGN stock, worth $300 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
1,017,278
Previous 1,061,727 4.19%
Holding current value
$300 Million
Previous $332 Million 1.19%
% of portfolio
0.3%
Previous 0.32%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$309.38 - $337.38 $13.8 Million - $15 Million
-44,449 Reduced 4.19%
1,017,278 $328 Million
Q2 2024

Aug 01, 2024

SELL
$262.75 - $319.31 $51,761 - $62,904
-197 Reduced 0.02%
1,061,727 $332 Million
Q1 2024

May 09, 2024

SELL
$268.87 - $324.56 $617,594 - $745,514
-2,297 Reduced 0.22%
1,061,924 $302 Million
Q4 2023

Feb 08, 2024

BUY
$255.7 - $288.46 $759,429 - $856,726
2,970 Added 0.28%
1,064,221 $307 Million
Q3 2023

Nov 09, 2023

BUY
$218.65 - $271.46 $2.4 Million - $2.98 Million
10,962 Added 1.04%
1,061,251 $285 Million
Q2 2023

Aug 08, 2023

BUY
$214.27 - $253.37 $2.58 Million - $3.05 Million
12,035 Added 1.16%
1,050,289 $233 Million
Q1 2023

May 11, 2023

BUY
$225.79 - $275.2 $8.27 Million - $10.1 Million
36,641 Added 3.66%
1,038,254 $251 Million
Q4 2022

Feb 14, 2023

BUY
$229.03 - $291.01 $6.99 Million - $8.88 Million
30,522 Added 3.14%
1,001,613 $263 Million
Q3 2022

Nov 10, 2022

BUY
$224.46 - $253.15 $10.3 Million - $11.6 Million
46,014 Added 4.97%
971,091 $219 Million
Q2 2022

Aug 11, 2022

SELL
$230.71 - $256.74 $4.89 Million - $5.44 Million
-21,198 Reduced 2.24%
925,077 $225 Million
Q1 2022

May 12, 2022

BUY
$219.27 - $242.57 $130,246 - $144,086
594 Added 0.06%
946,275 $229 Million
Q4 2021

Feb 10, 2022

BUY
$198.88 - $227.6 $2.66 Million - $3.05 Million
13,379 Added 1.44%
945,681 $213 Million
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $11.5 Million - $13.4 Million
-54,029 Reduced 5.48%
932,302 $198 Million
Q2 2021

Aug 05, 2021

SELL
$233.58 - $259.14 $12.9 Million - $14.3 Million
-55,094 Reduced 5.29%
986,331 $240 Million
Q1 2021

May 06, 2021

SELL
$221.91 - $258.6 $21.8 Million - $25.4 Million
-98,088 Reduced 8.61%
1,041,425 $259 Million
Q4 2020

Feb 10, 2021

SELL
$216.38 - $257.67 $4.75 Million - $5.66 Million
-21,963 Reduced 1.89%
1,139,513 $262 Million
Q3 2020

Nov 12, 2020

BUY
$234.65 - $260.95 $10.4 Million - $11.5 Million
44,191 Added 3.96%
1,161,476 $295 Million
Q2 2020

Aug 13, 2020

BUY
$197.81 - $242.74 $15.9 Million - $19.5 Million
80,302 Added 7.74%
1,117,285 $264 Million
Q1 2020

May 06, 2020

SELL
$182.24 - $241.7 $987,011 - $1.31 Million
-5,416 Reduced 0.52%
1,036,983 $210 Million
Q4 2019

Feb 05, 2020

SELL
$189.21 - $243.2 $1.49 Million - $1.91 Million
-7,870 Reduced 0.75%
1,042,399 $251 Million
Q3 2019

Oct 23, 2019

BUY
$174.11 - $208.62 $1.83 Million - $2.2 Million
10,536 Added 1.01%
1,050,269 $203 Million
Q2 2019

Aug 14, 2019

SELL
$166.7 - $195.41 $5.43 Million - $6.36 Million
-32,569 Reduced 3.04%
1,039,733 $192 Million
Q1 2019

May 01, 2019

BUY
$180.87 - $203.88 $6.1 Million - $6.87 Million
33,709 Added 3.25%
1,072,302 $204 Million
Q4 2018

Jan 31, 2019

SELL
$178.4 - $208.25 $23.1 Million - $27 Million
-129,554 Reduced 11.09%
1,038,593 $202 Million
Q3 2018

Nov 07, 2018

SELL
$185.29 - $208.89 $15.6 Million - $17.6 Million
-84,029 Reduced 6.71%
1,168,147 $242 Million
Q2 2018

Aug 06, 2018

SELL
$166.05 - $186.51 $11.7 Million - $13.1 Million
-70,381 Reduced 5.32%
1,252,176 $231 Million
Q1 2018

May 02, 2018

SELL
$169.43 - $198.0 $14.9 Million - $17.4 Million
-87,844 Reduced 6.23%
1,322,557 $225 Million
Q4 2017

Feb 09, 2018

BUY
$168.79 - $188.59 $7.79 Million - $8.71 Million
46,167 Added 3.38%
1,410,401 $245 Million
Q3 2017

Nov 06, 2017

BUY
$167.29 - $191.0 $228 Million - $261 Million
1,364,234
1,364,234 $254 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.